Schedule 13G ownership disclosure
Ultragenyx Pharmaceutical Inc
Common Stock, par value $0.001 per share · CUSIP: 90400D108
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- SANDS CAPITAL MANAGEMENT, LLC
Shares: 4,298,003.00 · Class: 4.7%
- SANDS FRANK M.
Shares: 4,298,003.00 · Class: 4.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001020066-25-000013
- Form type
- SCHEDULE 13G/A
- Filer
- SANDS CAPITAL MANAGEMENT, LLC
- CIK
- CIK 1020066
- Filed
- Feb 12, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership